TY  - JOUR
T1  - AXillary vs sentinel lymph node dissection for invasive breast cancer
AU  - Jatoi I
Y1  - 2011/06/08
N1  - 10.1001/jama.2011.750
JO  - JAMA
SP  - 2288
EP  - 2291
VL  - 305
IS  - 22
N2  - 
To the Editor: Dr Giuliano and colleagues stated that “Axillary recurrence is usually an early event, occurring at a median of 14.8 months in [the National Surgical Adjuvant Breast and Bowel Project] B04 [trial]; in that trial, only 7 of 68 axillary recurrences occurred more than 5 years after study entry.”1- 2 The authors then argued that, after a median follow-up of 6.3 years, further follow-up of patients in the American College of Surgeons Oncology Group Z0011 trial would not substantially alter the results of their study. Yet the authors ignored the fact that the risk of breast cancer recurrence is not only time-dependent but also dependent on tumor estrogen receptor (ER) status.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2011.750
UR  - http://dx.doi.org/10.1001/jama.2011.750
ER  -